Impact of ustekinumab on health‐related quality of life in Japanese patients with moderate‐to‐severe plaque psoriasis: Results from a randomized, double‐blind, placebo‐controlled phase 2 / 3 trial
Authors:
- Hidemi NakagawaHNHidemi Nakagawa
- The Japanese Ustekinumab Study GroupTGThe Japanese Ustekinumab Study Group
- 13 March 2012
- journal article
- research article
- Published by Wiley in The Journal of Dermatology
- Vol. 39 (9) , 761-769
Abstract
This study evaluates the effect of ustekinumab on health‐related quality of life (HRQoL) in Japanese patients with moderate‐to‐severe plaque psoriasis through 64 weeks. A total of 158 patients were randomized to receive subcutaneous injections of ustekinumab 45 mg (n = 64) or 90 mg (n = 62) at weeks 0, 4, and every‐12‐weeks, or placebo (n = 32) with crossover to ustekinumab at week 12. Secondary study endpoints included change in Dermatology Life Quality Index (DLQI) at week 12. Other assessments included the 36‐item Short Form health survey to assess Physical Component Summary (PCS) and Mental Component Summary (MCS) scores, and Psoriasis Disability Index (PDI), a psoriasis‐specific instrument to assess HRQoL. Baseline demographic and disease characteristics were similar across randomized treatment groups. Ustekinumab‐treated patients had significantly greater mean improvements in DLQI from baseline to week 12 (45 mg: 8.0 ± 6.5; 90 mg: 7.4 ± 6.5) than placebo‐treated patients (0.3 ± 5.3; P < 0.0001 for each), and these improvements were maintained through week 64. Also at week 12, significant improvements from baseline in PDI scores were observed in ustekinumab‐treated patients (45 mg: 8.6 ± 9.6; 90 mg: 12.0 ± 11.8) compared with placebo‐treated patients (−0.1 ± 4.2). Improvements in the PCS (45 mg: 7.8 ± 14.5; 90 mg: 5.1 ± 12.0) and MCS (45 mg: 5.3 ± 9.8; 90 mg: 5.8 ± 10.5) scores were also observed in ustekinumab‐treated patients at week 12. Placebo‐treated patients who crossed‐over to ustekinumab achieved improvements in HRQoL comparable to those observed in patients originally randomized to ustekinumab. Ustekinumab significantly improves HRQoL in Japanese patients with moderate‐to‐severe plaque psoriasis through week 64.Keywords
This publication has 41 references indexed in Scilit:
- Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trialJournal of the American Academy of Dermatology, 2010
- The Risk of Depression, Anxiety, and Suicidality in Patients With PsoriasisArchives of Dermatology, 2010
- A Multivariate Analysis of Clinical Severity, Psychological Distress and Psychopathological Traits in Psoriatic PatientsActa Dermato-Venereologica, 2010
- Comorbidities in Patients with PsoriasisThe American Journal of Medicine, 2009
- Experiences of appearance‐related teasing and bullying in skin diseases and their psychological sequelae: results of a qualitative studyScandinavian Journal of Caring Sciences, 2008
- The psychosocial and occupational impact of chronic skin diseaseDermatologic Therapy, 2008
- Prevalence and correlates of suicidal ideation among patients with skin diseaseJournal of the American Academy of Dermatology, 2006
- PsoriasisNew England Journal of Medicine, 2005
- Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasisBritish Journal of Dermatology, 1998
- The prevalence of psoriasis in the Mongoloid raceJournal of the American Academy of Dermatology, 1984